21.05.2015 Views

Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023

The new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. For more details : http://goo.gl/jGIpRr

The new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. For more details : http://goo.gl/jGIpRr

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

For More Information Visit : www.aarks<strong>to</strong>re.com<br />

Healthcare <strong>Market</strong> Research<br />

Reports


Summary<br />

GlobalData has released its new PharmaPoint Drug Evaluation report, “<strong>Lonsurf</strong><br />

(<strong>Colorectal</strong> <strong>Cancer</strong>) - <strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong>”. <strong>Colorectal</strong> cancer<br />

(CRC) is the second leading cause of mortality among cancer patients in the world <strong>and</strong> is<br />

the third most diagnosed cancer globally, <strong>and</strong> thus represents a huge burden on<br />

healthcare systems. This report focuses on the current treatment l<strong>and</strong>scape, unmet<br />

needs, current pipeline, <strong>and</strong> commercial opportunities in the colorectal cancer market,<br />

with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-,<br />

second-, third-line KRAS wild-type <strong>and</strong> mutation-positive, <strong>and</strong> fourth-line metastatic.<br />

In terms of targeted treatments, the metastatic CRC treatment l<strong>and</strong>scape is mature,<br />

including the br<strong>and</strong>ed treatments Avastin (bevacizumab), Erbitux (cetuximab), <strong>and</strong><br />

Vectibix (panitumumab), treatments that have extended the survival of metastatic<br />

patients compared <strong>to</strong> chemotherapy-only regimens. However, high unmet needs remain<br />

for the extension of survival of metastatic patients, <strong>and</strong> particularly those with KRAS<br />

mutation-positive disease, for whom the epidermal growth fac<strong>to</strong>r recep<strong>to</strong>r (EGFR)<br />

inhibi<strong>to</strong>rs Erbitux <strong>and</strong> Vectibix are not recommended.<br />

For More Information Visit : www.aarks<strong>to</strong>re.com


Scope<br />

- Overview of <strong>Colorectal</strong> <strong>Cancer</strong>, including epidemiology, etiology, symp<strong>to</strong>ms, diagnosis,<br />

pathology <strong>and</strong> treatment guidelines as well as an overview on the competitive<br />

l<strong>and</strong>scape.<br />

- Detailed information on <strong>Lonsurf</strong> including product description, safety <strong>and</strong> efficacy<br />

profiles as well as a SWOT analysis.<br />

- Sales forecast for <strong>Lonsurf</strong> for the <strong>to</strong>p eight countries from 2013 <strong>to</strong> <strong>2023</strong>.<br />

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan<br />

<strong>and</strong> China.<br />

For More Information Visit : www.aarks<strong>to</strong>re.com


Reasons <strong>to</strong> buy<br />

- Underst<strong>and</strong> <strong>and</strong> capitalize by identifying products that are most likely <strong>to</strong> ensure a<br />

robust return<br />

- Stay ahead of the competition by underst<strong>and</strong>ing the changing competitive l<strong>and</strong>scape<br />

for <strong>Colorectal</strong> <strong>Cancer</strong><br />

- Effectively plan your M&A <strong>and</strong> partnership strategies by identifying drugs with the<br />

most promising sales potential<br />

- Make more informed business decisions from insightful <strong>and</strong> in-depth analysis of<br />

<strong>Lonsurf</strong> performance<br />

- Obtain sales forecast for <strong>Lonsurf</strong> from 2013-<strong>2023</strong> in <strong>to</strong>p eight countries (the US,<br />

France, Germany, Italy, Spain, the UK, Japan <strong>and</strong> China)<br />

For More Information Visit : www.aarks<strong>to</strong>re.com


Table of Content<br />

1. INTRODUCTION<br />

2. Disease Overview<br />

3. Disease Management<br />

4. Competitive Assessment<br />

5. <strong>Lonsurf</strong><br />

6.Appendix<br />

For More Information Visit : www.aarks<strong>to</strong>re.com


List Of Tables<br />

Table 1: TNM <strong>and</strong> Staging Classification System for CRC 15<br />

Table 2: Symp<strong>to</strong>ms of <strong>Colorectal</strong> <strong>Cancer</strong> 16<br />

Table 3: Treatment Guidelines for CRC 21<br />

Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the<br />

Global <strong>Market</strong>s, 2013 22<br />

Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the<br />

Global <strong>Market</strong>s, 2013 23<br />

Table 6: Leading Treatments for CRC, 2014 32<br />

Table 7: Product Profile - <strong>Lonsurf</strong> 35<br />

Table 8: <strong>Lonsurf</strong> SWOT <strong>Analysis</strong>, 2014 37<br />

Table 9: Global Sales <strong>Forecast</strong>s ($m) for <strong>Lonsurf</strong> (TAS-102), 2013-<strong>2023</strong> 38<br />

Table 10: Average Body Weight <strong>and</strong> Surface Area Across the 8MM 49<br />

Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53<br />

For More Information Visit : www.aarks<strong>to</strong>re.com


Related Reports<br />

• Global Telemedicine market report<br />

• Global Clinical trial outsourcing report<br />

• Latest Chinese Guidance for Development, Evaluation, License Approval<br />

of Biosimilars<br />

• 2015 Strategies in the Global Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />

• 2015 Strategies in the European Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry<br />

<strong>Market</strong>s<br />

• 2015 Strategies in the French Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />

• 2015 Strategies in the German Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />

• 2015 Strategies in the Italian Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />

• 2015 Strategies in the Japanese Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />

• 2015 Strategies in the Spanish Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />

For More Information Visit : www.aarks<strong>to</strong>re.com


Follow Us<br />

https://www.facebook.com/aarks<strong>to</strong>redotcom<br />

https://twitter.com/aarks<strong>to</strong>re<br />

https://plus.google.com/+<strong>Aarks<strong>to</strong>re</strong>dotcom/posts<br />

https://www.linkedin.com/company/aarks<strong>to</strong>re-enterprise<br />

For More Information Visit : www.aarks<strong>to</strong>re.com


Contact Us<br />

Office Address<br />

Office No. - 809, 8th Floor,<br />

B-Wing, Mahaavir Icon,<br />

Plot No.- 89 & 90, Sec<strong>to</strong>r-15,<br />

CBD-Belapur, Navi Mumbai – 400614,<br />

Maharashtra, India.<br />

Mail us at contact@aarks<strong>to</strong>re.com<br />

24/7 Online Support: +91 9987295242<br />

General Inquiries : +91 - 22 2756 4953<br />

For More Information Visit : www.aarks<strong>to</strong>re.com

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!